1.	Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: TG4010.14/TIME, 8559, NCT01383148
2.	Cvac as Maintenance Treatment in Patients With EOC in Complete Remission Following First-Line Chemotherapy Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CAN-004, NCT01521143
3.	Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB, IIC and III Melanoma Patients Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 to 65 Sponsor: Other, Pharmaceutical / Industry Protocol IDs: CASVAC0401, NCT01729663
4.	Study of AlloStim In-Situ Vaccine in Pre-Treated Metastatic Breast Cancer Phase: Phase III, Phase II Type: Treatment Status: Approved-not yet active Age: 18 to 70 Sponsor: Pharmaceutical / Industry Protocol IDs: ITL-007-ATCR-MBC, NCT01741038
5.	Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: NLG0301, 1209-1184, NCT01774578
6.	Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 to 65 Sponsor: Pharmaceutical / Industry Protocol IDs: 020221, NCT00045968
7.	Phase III Randomized Study of Chemoimmunotherapy Comprising Gemcitabine Hydrochloride and Capecitabine With or Without Telomerase Peptide Vaccine GV1001 in Patients With Locally Advanced or Metastatic Pancreatic Cancer. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase III Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: CRUK-TELOVAC-V4, EUDRACT-2006-000461-10, EU-20683, ISRTCN43482138, NCT00425360, TELOVAC
8.	Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian Population Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EMR63325-012, NCT01015443
9.	Immunotherapy Study for Surgically Resected Pancreatic Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: NLG0405, OBA# 0912-1013, NCT01072981
10.	Gene Expression Profiling of Breast Cancer Cells Predict the Response of Malignant Pleural Effusion Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: GMPE, NCT01256801
11.	A Phase 3 Efficacy Study of a Recombinant Vaccinia Virus Vaccine to Treat Metastatic Prostate Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 to 85 Sponsor: Pharmaceutical / Industry Protocol IDs: BNIT-PRV-301, NCT01322490
12.	Efficacy and Safety Study of NeuVax(TM)(Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: NeuVax(TM) PH3-01, NCT01479244
13.	Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CDX110-04, NCT01480479
14.	Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients Phase: Phase III Type: Treatment Status: Active Age: 18 to 75 Sponsor: Pharmaceutical / Industry Protocol IDs: 103A-301, NCT01546571
15.	Study of the Telomerase Vaccine GV1001 to Treat Patients With Inoperable Stage III Non-small Cell Lung Cancer Phase: Phase III Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: KG 1/2012, NCT01579188
16.	Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC) Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: AGS-003-007, 2012-000871-17, NCT01582672
17.	Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 116428, 2012-003438-18, NCT01767467
18.	Phase I/II Study of Vaccination With Autologous Monocyte-Derived Dendritic Cells Transfected With RNAs Encoding For Melan-A, MAGE-3, and Survivin Antigens in Patients With Stage IV Cutaneous Melanoma. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: ERLANGEN-DERMA-ER-DC-06, EU-20317, NCT00074230
19.	Survivin Peptide Vaccination for Patients With Advanced Melanoma, Pancreatic, Colon and Cervical Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 19 to 90 Sponsor: Other Protocol IDs: SuMo-Sec-01, PEI 0899/01, IRB 07/03, NCT00108875
20.	Immunotherapy for Colorectal Cancers Using CEA-Pulsed Dendritic Cells and Subsequent IL-2 Treatment Phase: Phase II, Phase I Type: Treatment Status: Active Age: 20 to 75 Sponsor: Other Protocol IDs: 27MD02, NCT00154713
21.	The Role of Peptide-Loaded Dendritic Cells to Augment the Therapeutic Effect of Interleukin-2 Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 65 Sponsor: Other Protocol IDs: pepDCIL2- HMO-CTIL, NCT00279058
22.	Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients With Relapsed Stage III or IV Ovarian Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: A/100/0501, NCT00660101
23.	Immunization With AFP + GM CSF Plasmid Prime and AFP Adenoviral Vector Boost in Patients With Hepatocellular Carcinoma Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 80 Sponsor: Other Protocol IDs: 04-101, R01 CA104524, NCT00669136
24.	Phase?/? Study of URLC10-177 and TTK-567 Peptide Vaccine Combined With CpG7909 in Patients With Esophageal Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 20 to 80 Sponsor: Other Protocol IDs: WEUTC, NCT00669292
25.	Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Non-Small Cell Lung Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 20 to 85 Sponsor: Other Protocol IDs: IMS-NSCLC02, NCT00673777